Published in Hepatology on May 01, 2007
Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol (2013) 2.22
Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy. J Gastroenterol (2013) 1.07
Availability of monitoring serum HBV DNA plus RNA during nucleot(s)ide analogue therapy. J Gastroenterol (2013) 0.77
Detectability and clinical significance of serum hepatitis B virus ribonucleic acid. Hepatobiliary Surg Nutr (2015) 0.76
Single-Nucleotide Resolution Mapping of Hepatitis B Virus Promoters in Infected Human Livers and Hepatocellular Carcinoma. J Virol (2016) 0.76
HBV Capsid Assembly Modulators, but not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants. Antimicrob Agents Chemother (2017) 0.75
Serum HBV DNA, RNA and HBsAg: which correlated better to intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment? J Clin Microbiol (2017) 0.75
Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc (2006) 5.42
Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med (2002) 5.30
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis (2012) 3.91
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol (2007) 3.14
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Electrical switching of the vortex core in a magnetic disk. Nat Mater (2007) 2.76
Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation (2003) 2.69
Endoscopic submucosal dissection for colorectal neoplasia: possibility of standardization. Gastrointest Endosc (2007) 2.62
Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J (2004) 2.50
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol (2012) 2.34
Theory of current-driven domain wall motion: spin transfer versus momentum transfer. Phys Rev Lett (2004) 2.27
Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol (2012) 2.24
Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol (2013) 2.22
Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer (2010) 2.20
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol (2011) 2.18
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
Clinical features of pharyngeal intraepithelial neoplasias and outcomes of treatment by endoscopic submucosal dissection. Gastrointest Endosc (2012) 2.12
Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet (2011) 2.09
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet (2005) 2.08
Magnifying endoscopy with narrow band imaging for diagnosis of colorectal tumors. Gastrointest Endosc (2007) 2.04
Genetic polymorphisms and esophageal cancer risk. Int J Cancer (2007) 2.02
Feasibility of the extracardiac conduit Fontan procedure in patients weighing less than 10 kilograms. J Thorac Cardiovasc Surg (2008) 1.97
A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet (2011) 1.96
Narrow-band imaging magnification predicts the histology and invasion depth of colorectal tumors. Gastrointest Endosc (2009) 1.92
Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci (2006) 1.90
Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet (2010) 1.90
Optical biopsy of GI lesions by reflectance-type laser-scanning confocal microscopy. Gastrointest Endosc (2007) 1.87
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut (2010) 1.85
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 1.85
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology (2009) 1.83
G to A hypermutation of hepatitis B virus. Hepatology (2005) 1.83
Clinicopathologic features and endoscopic resection of early primary nonampullary duodenal carcinoma. J Clin Gastroenterol (2003) 1.76
RNF5, a RING finger protein that regulates cell motility by targeting paxillin ubiquitination and altered localization. Mol Cell Biol (2003) 1.75
Biliary complications after duct-to-duct biliary reconstruction in living-donor liver transplantation: causes and treatment. World J Surg (2007) 1.73
Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. J Gastroenterol Hepatol (2012) 1.72
Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection. J Gastroenterol (2008) 1.71
Risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal neoplasms. Int J Colorectal Dis (2014) 1.70
Improved visibility of lesions of the small intestine via capsule endoscopy with computed virtual chromoendoscopy. Gastrointest Endosc (2011) 1.67
Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci (2008) 1.67
Multiple carcinoid tumors of the ileum preoperatively diagnosed by enteroscopy with the double-balloon technique. Gastrointest Endosc (2005) 1.67
Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest (2009) 1.65
Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv (2011) 1.63
Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer (2003) 1.60
Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol (2008) 1.59
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol (2010) 1.56
Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol (2011) 1.54
CDH13 Polymorphisms are Associated with Adiponectin Levels and Metabolic Syndrome Traits Independently of Visceral Fat Mass. J Atheroscler Thromb (2015) 1.50
Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage. AJR Am J Roentgenol (2002) 1.48
Frequent somatic mutations of mitochondrial DNA in traditional serrated adenomas but not in sessile serrated adenomas of the colorectum. J Gastroenterol Hepatol (2011) 1.47
Chronic hepatitis B in patients coinfected with human immunodeficiency virus in Japan: a retrospective multicenter analysis. J Infect Chemother (2012) 1.47
Current status and future perspectives of endoscopic submucosal dissection for colorectal tumors. Dig Endosc (2012) 1.47
Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. J Gastroenterol Hepatol (2010) 1.46
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer (2002) 1.46
Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology (2005) 1.46